4516.T Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 апр. 2024 @ 09:15):

Stats
Объем за сегодня	176 200
Средний объем	335 359
Рыночная капитализация	291.97B
EPS	¥0 ( 2024-02-08 )
Дата следующего отчета о доходах	( ¥39.17 ) 2024-05-09
Last Dividend	¥57.00 ( 2023-03-30 )
Next Dividend	¥0 ( N/A )
P/E	12.09
ATR14	¥2.00 (0.05%)

Объем Корреляция

Длинно: 0.02 (neutral)

Кратко: 0.81 (strong)

Signal:(58.562) Same movement expected

Nippon Shinyaku Co., Ltd. Корреляция

10 Самые положительные корреляции

10 Самые отрицательные корреляции

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Nippon Shinyaku Co., Ltd. Корреляция - Валюта/Сырье

-0.14
( neutral )

-0.53
( weak negative )

-0.18
( neutral )

-0.05
( neutral )

-0.24
( neutral )

0.68
( moderate )

Nippon Shinyaku Co., Ltd. Финансовые показатели

Annual	2022
Выручка:	¥144.18B
Валовая прибыль:	¥88.20B (61.17 %)
EPS:	¥338.70

FY	2022
Выручка:	¥144.18B
Валовая прибыль:	¥88.20B (61.17 %)
EPS:	¥338.70

FY	2022
Выручка:	¥137.48B
Валовая прибыль:	¥87.29B (63.49 %)
EPS:	¥370.97

FY	2021
Выручка:	¥121.89B
Валовая прибыль:	¥71.93B (59.02 %)
EPS:	¥307.37

Financial Reports:

No articles found.

Nippon Shinyaku Co., Ltd. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥57.00 (N/A)	¥0 (N/A)	¥57.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Nippon Shinyaku Co., Ltd. Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.77 - Stable (15.38%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥5.00	2001-03-27
Last Dividend	¥57.00	2023-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	45	--
Total Paid Out	¥829.00	--
Avg. Dividend % Per Year	0.00%	--
Score	4.38	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	5.77
Div. Directional Score	9.75	--

Next Divdend (Est)
(2024-07-22)

¥0 Estimate 0.00 %

Dividend Stability

0.10 Very Bad

Dividend Score

4.38

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
8065.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
7337.T	Ex Dividend Junior	2023-09-28	Semi-Annually	0.00%
6586.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
5932.T	Ex Dividend Junior	2023-11-29	Annually	0.00%
4612.T	Ex Dividend Knight	2023-12-28	Semi-Annually	0.00%
3839.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
3091.T	Ex Dividend Knight	2023-12-28	Semi-Annually	0.00%
1961.T	Ex Dividend Junior	2023-09-28	Semi-Annually	0.00%
9972.T	Ex Dividend Junior	2023-11-29	Annually	0.00%
8963.T	Ex Dividend Junior	2023-12-28	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.164	1.500	6.72	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0974	1.200	6.75	8.10	[0 - 0.3]
returnOnEquityTTM	0.117	1.500	9.81	10.00	[0.1 - 1]
payoutRatioTTM	0.331	-1.000	6.69	-6.69	[0 - 1]
currentRatioTTM	5.92	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	4.17	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	2.11	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.00826	-1.500	9.86	-10.00	[0 - 0.6]
interestCoverageTTM	264.20	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	321.86	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	163.50	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.00953	-1.500	9.96	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.646	1.000	2.57	2.57	[0.2 - 0.8]
operatingProfitMarginTTM	0.226	1.000	7.47	7.47	[0.1 - 0.6]
cashFlowToDebtRatioTTM	10.59	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.593	0.800	9.38	7.50	[0.5 - 2]
Total Score				13.73

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	12.10	1.000	8.88	0	[1 - 100]
returnOnEquityTTM	0.117	2.50	9.88	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	163.50	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	2.86	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	321.86	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0.331	1.500	6.69	-6.69	[0 - 1]
pegRatioTTM	-1.981	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.147	1.000	8.81	0	[0.1 - 0.5]
Total Score				5.77

Nippon Shinyaku Co., Ltd.

Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Switzerland, and internationally. The company operates through Pharmaceuticals and Functional Food segments. It offers drugs for urological diseases, inflammation and allergies, hematologic malignancies, cardiovascular and metabolic diseases, gastrointestinal disorders, and other diseases. The company's products include Zalutia for urinary disorder caused by benign prostatic; Eviprostat for prostatic hypertrophy; Bladderon for pollakisuria; Estracyt for prostate cancer; Cialis for erectile dysfunction; Vidaza for myelodysplastic syndrome; Cylocide for solid tumor and acute leukemia; CylocideN for relapsed and refractory acute leukemia and malignant lymphoma; Gazyva for humanized anti-CD20 monoclonal antibody; Defiterio sinusoidal obstruction syndrome; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. Nippon Shinyaku Co., Ltd.'s products also comprise Uptravi, Adcirca, and Opsumit for pulmonary arterial hypertension; VILTEPSO for muscular dystrophy; Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler solution for allergic rhinitis; Azunol Gargle liquid, a gargling solution containing azulene; Isobide for oral osmotic diuresis/meniere's disease; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; Regtect for maintaining alcohol abstinence; and Onetram and Tramal for cancer and chronic pain. In addition, it researches, develops, and markets drugs in the areas of gynecology, otorhinolaryngology, and orthopedics. Further, the company provides functional foods, such as health food ingredients, preservatives, protein preparations, supplements, and spice and condiments. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.